Skip to content

Compare Mitomycin C with Bevacizumab-methycelluse Mixture in Cataract and Glaucoma surgery

Intraoperative Mitomycin C Versus Bevacizumab-methycelluse-mixture in Combined Phacoemulsification and Non Penetrating Deep Sclerectomy on Intraocular pressure in patients suffering from open angle glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016122231450N2
Enrollment
30
Registered
2017-01-26
Start date
2017-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma. Primary open-angle glaucoma Glaucoma (primary)(residual stage): capsular with pseudoexfoliation of lens chronic simple low-tension pigmentary

Interventions

Intervention 1: Intervention group 2: patients in this group will be put under general anesthesia. At first, a fornix-based conjunctival flap is created. Then, a 4x 4 mm outer parabolic flap, approxim
Treatment - Drugs
Intervention group 1: patients in this group will be put under general anesthesia. First, a fornix-based conjunctival flap is created. Then, a 4x 4 mm outer parabolic flap, approximately 200 µm thick,

Sponsors

Vice Chancellor for research of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: The need for cataract surgery in patients with open-angle glaucoma that have glaucomatous progressive cupping and deterioration of the visual field; Diagnosis of open-angle glaucoma on maximally tolerated medical therapy with uncontrolled IOP; The need for cataract surgery in patients with open-angle glaucoma requiring multiple medications to control IOP; Patients suffering from glaucoma and cataract with impaired vision; Patients’ willingness to participate in the study. Exclusion criteria: Patients with contraindications to bevacizumab such as arterial thromboembolic events, uncontrolled hypertension, and congestive heart failure,..; Discernable congenital abnormality of the anterior chamber angle; Ocular infection; Previous ocular surgery; Uveitis; Corneal diseases that could affect IOP or its measurement such as corneal opacity, large pterygium, ...; Patients who are less than 40 years? Diabetes; Neovascular glaucoma? Patient with any systemic or ocular complication.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Intraocular pressure. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Goldmann applanation tonometry (mmHg).

Secondary

MeasureTime frame
Visual acuity. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Snellen charts.;Visual field. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Humphrey 24-2 SITA Standard perimetry (HFA 24-2) Or(HFA 10-2).;Beleb morphology. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Moorfields Bleb Grading System.;Endophthalmitis. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Examination slitlamp.;Conjunctival necrosis. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Examination slitlamp.;Hypertension. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Sphygmomanometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtena Latifi

Tabriz University of Medical Sciences

info@elibrary.tbzmed.ac.ir; dln@tbzmed.ac.ir+98 41 3335 5921

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026